Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,695.97
(
-0.28%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 173648

Sunday, 02/02/2014 5:31:28 PM

Sunday, February 02, 2014 5:31:28 PM

Post# of 257269

Do we have a breakdown of [GILD’s] ION trials by GT1a vs. 1b?

GILD hasn’t disclosed the GT1a/GT1b breakdown in any of the ‘ION’ studies; they will presumably do so at the EASL conference in April. (Ditto for GILD’s disclosure of the subset data for cirrhotic patients in ION-1 and ION-2.)

…the percentage cirrhosis in the ABBV trials?

There were no cirrhotic patients in any of the ABBV/ENTA trials except TURQUOISE-2, which was 100% cirrhotics.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today